SMYD3 Impedes Small Cell Lung Cancer Sensitivity to Alkylation Damage Through RNF113A Methylation-Phosphorylation Cross-talk

Overview

Journal Cancer Discov

Specialty Oncology

Date 2022 Jul 12

PMID 35819319

Authors

Valentina Lukinovic

Simone Hausmann

Gael S Roth

Clement Oyeniran

Tanveer Ahmad

Ning Tsao

Joshua R Brickner

Alexandre G Casanova

Florent Chuffart

Ana Morales Benitez

Jessica Vayr

Rebecca Rodell

Marianne Tardif

Pascal W T C Jansen

Yohann Coute

Michiel Vermeulen

Pierre Hainaut

Pawel K Mazur

Nima Mosammaparast

Nicolas Reynoird

Affiliations

Soon will be listed here.

Abstract

Significance: SCLC rapidly becomes resistant to conventional chemotherapy, leaving patients with no alternative treatment options. Our data demonstrate that SMYD3 upregulation and RNF113A methylation in SCLC are key mechanisms that control the alkylation damage response. Notably, SMYD3 inhibition sensitizes cells to alkylating agents and promotes sustained SCLC response to chemotherapy. This article is highlighted in the In This Issue feature, p. 2007.

Citing Articles

Therapeutic targeting potential of the protein lysine and arginine methyltransferases to reverse cancer chemoresistance.

Micallef I, Fenech K, Baron B Front Mol Biosci. 2024; 11:1455415.

PMID: 39703687 PMC: 11656028. DOI: 10.3389/fmolb.2024.1455415.

SMYD family in cancer: epigenetic regulation and molecular mechanisms of cancer proliferation, metastasis, and drug resistance.

Han T, Kim D, Son M, Cho H Exp Mol Med. 2024; 56(11):2325-2336.

PMID: 39482529 PMC: 11611910. DOI: 10.1038/s12276-024-01326-8.

Targeting PRMT3 impairs methylation and oligomerization of HSP60 to boost anti-tumor immunity by activating cGAS/STING signaling.

Shi Y, Wu Z, Liu S, Zuo D, Niu Y, Qiu Y Nat Commun. 2024; 15(1):7930.

PMID: 39256398 PMC: 11387718. DOI: 10.1038/s41467-024-52170-3.

Small Cell Lung Cancer-An Update on Chemotherapy Resistance.

Ying Q, Fan R, Shen Y, Chen B, Zhang J, Li Q Curr Treat Options Oncol. 2024; 25(8):1112-1123.

PMID: 39066852 DOI: 10.1007/s11864-024-01245-w.

New insights into immune cells in cancer immunotherapy: from epigenetic modification, metabolic modulation to cell communication.

Qin S, Xie B, Wang Q, Yang R, Sun J, Hu C MedComm (2020). 2024; 5(6):e551.

PMID: 38783893 PMC: 11112485. DOI: 10.1002/mco2.551.

References

Schaffer B, Park K, Yiu G, Conklin J, Lin C, Burkhart D . Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma. Cancer Res. 2010; 70(10):3877-83. PMC: 2873158. DOI: 10.1158/0008-5472.CAN-09-4228. View

Chen P, Kuang P, Wang L, Li W, Chen B, Liu Y . Mechanisms of drugs-resistance in small cell lung cancer: DNA-related, RNA-related, apoptosis-related, drug accumulation and metabolism procedure. Transl Lung Cancer Res. 2020; 9(3):768-786. PMC: 7354133. DOI: 10.21037/tlcr-19-547. View

Koyen A, Madden M, Park D, Minten E, Kapoor-Vazirani P, Werner E . EZH2 has a non-catalytic and PRC2-independent role in stabilizing DDB2 to promote nucleotide excision repair. Oncogene. 2020; 39(25):4798-4813. PMC: 7305988. DOI: 10.1038/s41388-020-1332-2. View

Kondo N, Takahashi A, Ono K, Ohnishi T . DNA damage induced by alkylating agents and repair pathways. J Nucleic Acids. 2010; 2010:543531. PMC: 2989456. DOI: 10.4061/2010/543531. View

Shostak K, Jiang Z, Charloteaux B, Mayer A, Habraken Y, Tharun L . The X-linked trichothiodystrophy-causing gene RNF113A links the spliceosome to cell survival upon DNA damage. Nat Commun. 2020; 11(1):1270. PMC: 7062854. DOI: 10.1038/s41467-020-15003-7. View

Mitchell L, Boriack-Sjodin P, Smith S, Thomenius M, Rioux N, Munchhof M . Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 Inhibitor. ACS Med Chem Lett. 2016; 7(2):134-8. PMC: 4753551. DOI: 10.1021/acsmedchemlett.5b00272. View

Fushiki H, Kanoh-Azuma T, Katoh M, Kawabata K, Jiang J, Tsuchiya N . Quantification of mouse pulmonary cancer models by microcomputed tomography imaging. Cancer Sci. 2009; 100(8):1544-9. PMC: 11158256. DOI: 10.1111/j.1349-7006.2009.01199.x. View

Bouyssie D, Hesse A, Mouton-Barbosa E, Rompais M, Macron C, Carapito C . Proline: an efficient and user-friendly software suite for large-scale proteomics. Bioinformatics. 2020; 36(10):3148-3155. PMC: 7214047. DOI: 10.1093/bioinformatics/btaa118. View

Chu V, Weber T, Graf R, Sommermann T, Petsch K, Sack U . Efficient generation of Rosa26 knock-in mice using CRISPR/Cas9 in C57BL/6 zygotes. BMC Biotechnol. 2016; 16:4. PMC: 4715285. DOI: 10.1186/s12896-016-0234-4. View

10.

Nagel R, Avelar A, Aben N, Proost N, van de Ven M, van der Vliet J . Inhibition of the Replication Stress Response Is a Synthetic Vulnerability in SCLC That Acts Synergistically in Combination with Cisplatin. Mol Cancer Ther. 2019; 18(4):762-770. PMC: 6451635. DOI: 10.1158/1535-7163.MCT-18-0972. View

11.

Travaglini K, Nabhan A, Penland L, Sinha R, Gillich A, Sit R . A molecular cell atlas of the human lung from single-cell RNA sequencing. Nature. 2020; 587(7835):619-625. PMC: 7704697. DOI: 10.1038/s41586-020-2922-4. View

12.

Kesavan K, Lobel-Rice K, Sun W, Lapadat R, Webb S, Johnson G . MEKK2 regulates the coordinate activation of ERK5 and JNK in response to FGF-2 in fibroblasts. J Cell Physiol. 2004; 199(1):140-8. DOI: 10.1002/jcp.10457. View

13.

Jiang L, Yang K, Guan Q, Mi D, Wang J . Cisplatin plus etoposide versus other platin-based regimens for patients with extensive small-cell lung cancer: a systematic review and meta-analysis of randomised, controlled trials. Intern Med J. 2012; 42(12):1297-309. DOI: 10.1111/j.1445-5994.2012.02821.x. View

14.

Inamura K . Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification. Front Oncol. 2017; 7:193. PMC: 5581350. DOI: 10.3389/fonc.2017.00193. View

15.

Tsao N, Brickner J, Rodell R, Ganguly A, Wood M, Oyeniran C . Aberrant RNA methylation triggers recruitment of an alkylation repair complex. Mol Cell. 2021; 81(20):4228-4242.e8. PMC: 8931856. DOI: 10.1016/j.molcel.2021.09.024. View

16.

Raymond C, Soriano P . High-efficiency FLP and PhiC31 site-specific recombination in mammalian cells. PLoS One. 2007; 2(1):e162. PMC: 1764711. DOI: 10.1371/journal.pone.0000162. View

17.

Liu S, Hausmann S, Carlson S, Fuentes M, Francis J, Pillai R . METTL13 Methylation of eEF1A Increases Translational Output to Promote Tumorigenesis. Cell. 2019; 176(3):491-504.e21. PMC: 6499081. DOI: 10.1016/j.cell.2018.11.038. View

18.

Black J, Van Rechem C, Whetstine J . Histone lysine methylation dynamics: establishment, regulation, and biological impact. Mol Cell. 2012; 48(4):491-507. PMC: 3861058. DOI: 10.1016/j.molcel.2012.11.006. View

19.

Mazur P, Reynoird N, Khatri P, Jansen P, Wilkinson A, Liu S . SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer. Nature. 2014; 510(7504):283-7. PMC: 4122675. DOI: 10.1038/nature13320. View

20.

Jenuwein T, Allis C . Translating the histone code. Science. 2001; 293(5532):1074-80. DOI: 10.1126/science.1063127. View